ORIGINAL ARTICLE
Histological perspective on the effects of tumor-associated macrophages in the tumor microenvironment surrounding papillary thyroid carcinoma
 
More details
Hide details
 
Submission date: 2016-09-27
 
 
Final revision date: 2016-12-04
 
 
Acceptance date: 2016-12-05
 
 
Publication date: 2017-02-10
 
 
Pol J Pathol 2016;67(4):332-344
 
KEYWORDS
TOPICS
ABSTRACT
Tumor-associated macrophages (TAMs) are one of the most noticeable elements of the tumor microenvironment. The present study investigated the relationships between the density of CD163 immunolabeled M2-like TAMs with other histological properties of the tumor microenvironment and clinipathological features in 90 patients with papillary thyroid carcinomas (PTC). The percentage of TAMs was higher in tumors with significant lymphocytic tumor response (p = 0.020), in tumors with a significant degree of stromal tumor response (p = 0.014), those with infiltrative tumor borders (p = 0.029), in conventional variant papillary carcinoma (p = 0.032), and in patients with autoantibodies for thyroid peroxidase (p = 0.014). The tumors associated with lymphocytic thyroiditis had lower numbers of TAMs (p = 0.027). In conclusion, for the first time, the present study attempts to establish a full assessment of interactions of CD163 expressing M2-like TAMs with the triad of primary tumor- tumor microenvironment- tumor behavior and above all, with markers of autoimmunity. Thus, these alternatively polarized macrophages may act in tumor progression and dissemination according to their various products, which may be ordered by tumor cells or neighboring immune cells. The molecular studies may reveal their roles in various tumors and may improve the therapy strategies targeting TAMs in various malignant tumors, including PTCs.
REFERENCES (42)
1.
Qing W, Fang WY, Ye L, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012; 22: 905-910.
 
2.
Can N, Tastekin E, Ozyilmaz F, et al. Histopathological evidence of lymph node metastasis in papillary thyroid carcinoma. Endocr Pathol 2015; 26: 218-228.
 
3.
Proietti A, Ugolini C, Melillo RM, et al. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 2011; 21: 1209-1215.
 
4.
Cunha LL, Morari EC, Guihen AC, et al. Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer. Endocr Relat Cancer 2012; 19: 31-36.
 
5.
Caillou B, Talbot M, Weyemi U, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One 2011; 6: e22567.
 
6.
Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012; 7: e50946.
 
7.
Fang W, Ye L, Shen L, et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 2014; 35: 1780-1787.
 
8.
Cunha LL, Marcello MA, Ward LS. The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr Relat Cancer 2014; 21: 85-103.
 
9.
Schroder S, Schwarz W, Rehpenning W, et al. Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am J Clin Pathol 1988; 89: 295-300.
 
10.
van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 1992; 67: 166-174.
 
11.
Ryder M, Ghossein RA, Ricarte-Filho JC, et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008; 15: 1069-1074.
 
12.
Brooks E, Simmons-Arnold L, Naud S, et al. Multinucleated giant cells’ incidence, immune markers, and significance: a study of 172 cases of papillary thyroid carcinoma. Head Neck Pathol 2009; 3: 95-99.
 
13.
Kim BH. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab 2013; 28:.
 
14.
178-179.
 
15.
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014; 41: 49-61.
 
16.
Cho SW, Kim YA, Sun HJ, et al. CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma. Endocr Relat Cancer 2016; 23: 113-124.
 
17.
Corliss BA, Azimi MS, Munson JM, et al. Macrophages: an inflammatory link between angiogenesis and lymphangiogenesis. Microcirculation 2016; 23: 95-121.
 
18.
Ryder M, Gild M, Hohl TM, et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One 2013; 8: e54302.
 
19.
Kim S, Cho SW, Min HS, et al. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab 2013; 28: 192-198.
 
20.
Herrmann G, Schumm-Draeger PM, Muller C, et al. T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. J Cancer Res Clin Oncol 1994; 120: 651-656.
 
21.
Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105: 1-8.
 
22.
Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727.
 
23.
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
 
24.
Karnevi E, Andersson R, Rosendahl AH. Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. Immunol Cell Biol 2014; 92: 543-552.
 
25.
Jung YY, Lee CH, Park SY, et al. Characteristic tumor growth patterns as novel histomorphologic predictors for lymph node metastasis in papillary thyroid carcinoma. Hum Pathol 2013; 44: 2620-2627.
 
26.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
 
27.
Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
 
28.
Tagliabue A, Herberman RB, Arthur LO, et al. Cellular immunity to tumor-associated antigens of transplantable mammary tumors of C3H/HeN mice. Cancer Res 1979; 39: 35-41.
 
29.
Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
 
30.
Cunha LL, Tincani AJ, Assumpcao LV, et al. Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) 2011; 66: 1203-1208.
 
31.
Yu H, Huang X, Liu X, et al. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 2013; 44: 172-181.
 
32.
Stanic B, van de Veen W, Wirz OF, et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol 2015; 135: 771-780 e778.
 
33.
Rotondi M, Coperchini F, Pignatti P, et al. Interferon-gamma and tumor necrosis factor-alpha sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? J Clin Endocrinol Metab 2013; 98: 308-313.
 
34.
Dong S, Xia Q, Wu YJ. High TPOAb Levels (>1300 IU/mL) indicate multifocal PTC in Hashimoto’s thyroiditis patients and support total thyroidectomy. Otolaryngol Head Neck Surg 2015; 153: 20-26.
 
35.
Eloy C, Santos J, Cameselle-Teijeiro J, et al. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch 2012; 460: 587-600.
 
36.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol 2016; 2: 1023-1029.
 
37.
Komohara Y, Niino D, Saito Y, et al. Clinical significance of CD163(+) tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 945-951.
 
38.
Angell TE, Lechner MG, Jang JK, et al. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014; 24: 1385-1393.
 
39.
Jung KY, Cho SW, Kim YA, et al. Cancers with Higher density of tumor-associated macrophages were associated with poor survival rates. J Pathol Transl Med 2015; 49: 318-324.
 
40.
Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
 
41.
Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102: 1424-1431.
 
42.
Niino D, Komohara Y, Murayama T, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278-283.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top